SLC1A4 and Alzheimer disease: As D-serine is one of the contributors to cognitive decline in AD and is currently of great interest as a target for AD drug development (Orzylowski et al., 2021), understanding the contribution of ASCT1 to altered D-serine levels in AD brains can open new horizons for the development of drugs targeting this transporter to regulate D-serine brain levels.